HBI-3000 Clinical Advisory Board
Jeffrey L. Anderson, MD, Professor of Medicine, University of Utah and Chief of Cardiology, Intermountain Medical Center. A major contributor to cardiovascular research over a broad area including anti-arrhythmic therapies, genetic polymorphisms and new risk factors for cardiovascular disease
Peter Fitzgerald, MD, PhD, Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. Additionally, Professor in the Stanford Departments of Medicine and Engineering. An Interventional Cardiologist with broad expertise in diagnostic and therapeutic device development
Peter R. Kowey, MD, Professor of Medicine and Clinical Pharmacology at Jefferson Medical College and a pioneer in the development of many anti-arrhythmic drugs and anti-tachycardia devices
Benedict Lucchesi, MD, PhD, Professor of Pharmacology at the University of Michigan Medical School Department of Pharmacology for more than 40 years and contributor to more than 370 publications in basic pharmacology and drug development
Stanley Nattel, MD, Paul-David Chair in Cardiovascular Electrophysiology, Professor of Medicine, University of Montreal, Director, Electrophysiology Research Program Montreal Heart Institute Research Center, University of Montreal
Denis Roy, MD, Montreal Heart Institute, Professor and Chair of the Department of Medicine at the University of Montreal and Principal Investigator of the recently completed Atrial Fibrillation and Congestive Heart Failure multi-center international trial
Eric Topol, MD, Chief Academic Officer for Scripps Health, former chairman of Cardiovascular Medicine at the Cleveland Clinic for 15 years, and recognized by the Institute of Scientific Information as one of the top 10 cited researchers in medicine over the past decade
HBI-8000 Clinical Advisory Board
Daniel D. Von Hoff, MD, Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute), Chief Scientific Officer for US Oncology, and Chief Scientific Officer, Scottsdale Clinical Research Institute for Scottsdale Healthcare's Clinical Research Institute
Bruce A. Chabner, MD, Chief of Hematology/Oncology at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School , and Associate Director for Clinical Science of the Dana-Farber/Harvard Cancer Center
Pamela Munster, MD, Associate Professor, Dept of Medicine (Hematology/Oncology) UCSF, Director Early Phase Clinical Trial Program, UCSF, and Associate Director, Investigational Therapeutics, Helen Diller Family Comprehensive Cancer Center, UCSF